ADmit Therapeutics is a biotechnology spin‑off from the Instituto de Investigación Biomédica de Bellvitge (IDIBELL), founded in late 2017. The company develops MAP‑AD, a blood‑based diagnostic that uses an algorithm to stratify patients with mild cognitive impairment (MCI) by their probability of progression to Alzheimer’s disease through epigenetic analysis of mitochondrial DNA methylation signatures. Its approach combines patented biomarker patterns and a novel algorithm to link methylation patterns with clinical prognosis. ADmit positions MAP‑AD as a tool for clinicians to optimize patient stratification and for pharmaceutical companies to improve selection in clinical trials, potentially reducing time and costs. The company plans to use the recent financing to obtain CE marking and FDA approval to commercialize MAP‑AD in Europe and the United States. Marta Barrachina is cited as CEO leading the team and scientific capabilities behind the technology. ADmit Therapeutics, a spin‑off from IDIBELL founded in late 2017, is developing a blood test for early detection of Alzheimer’s based on epigenetic analysis of mitochondrial DNA. The company’s approach rests on the hypothesis that mitochondrial dysfunction precedes the appearance of amyloid and tau aggregates, creating a diagnostic window before clinical decline. ADmit is training a predictive algorithm on more than 300 blood samples and planned to begin clinical validation the year after the article (2021). Its near‑term regulatory goal is to obtain CE marking and reach the market by 2023. The team is led by CEO and co‑founder Marta Barrachina, with clinical co‑founders and advisers Ramón Reñé and Jordi Gascón. Financially, ADmit has accumulated multiple funding sources including grants, equity crowdfunding and private investments, totaling nearly €5 million in under three years. ADmit Therapeutics develops an in vitro early diagnostic test for Alzheimer's disease using blood samples, plus an associated predictive algorithm and software for patient diagnosis. The company is a spin-off from the Bellvitge Biomedical Research Institute (IDIBELL) and was founded in late 2017. It has received national and European grants and private investments from backers including Ship2B, GENESIS Biomed and BStartup10. ADmit aims to obtain a CE mark in 2023 to commercialize its diagnostic algorithm and software. The business is pursuing clinical validation funding and is participating in impact acceleration programs such as S2B Tech4Health. ADmit Therapeutics develops an early diagnostic test for Alzheimer’s disease and is working toward a laboratory IVD device intended to obtain CE marking by late 2022. The company plans to use recent funding to advance its diagnostic development, begin clinical validation, and secure commercial partner agreements. Management says the test could optimize patient recruitment for clinical trials and improve the chances of demonstrating drug efficacy. The company intends to valorize its clinical proof of concept and reinforce its intellectual property with the new funds. ADmit operates in the biotechnology/genetic engineering sector and is based in L'Hospitalet de Llobregat (Barcelona).

Total raised

$10M

Funding rounds

4

Latest round

Equity

Latest activity

Oct 2023